To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
Incyte Corporation
Celgene
CTI BioPharma
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center